Status:
RECRUITING
Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)
Lead Sponsor:
Fudan University
Conditions:
Locally Advanced Rectal Cancer
Neoadjuvant Therapy
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
SERRAC is a prospective, multicentre, randomized phase II trial. 138 LARC (T3-4/N+M0, distance from anal verge ≤10cm) patients will be treated with neoadjuvant therapy and assigned to Group A and Grou...
Eligibility Criteria
Inclusion
- Age 18-75 years, gender not limited
- Pathologically confirmed rectal adenocarcinoma
- ≤10 cm from the anus
- Baseline stage T3-4/N+
- No distant metastasis
- MSI/MMR status MSS/pMMR
- Karnofsky performance status score ≥70
- No prior chemotherapy or other anti-cancer treatment prior to enrollment
- No prior immunotherapy prior to enrollment
- Ability to comply with the study protocol
- Written informed consent
Exclusion
- Pregnancy or breast-feeding women;
- Known history of other malignancies within 5 years;
- Known history of previous anti-tumor treatment, including radiotherapy, chemotherapy, immune checkpoint inhibitors, T cell-related therapy, etc;
- Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy);
- Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction;
- Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment;
- Uncontrolled infection which needs systemic therapy;
- Active autoimmune disease or immunodeficiencies, known history of organ transplantation or systematic use of immunosuppressive agents;
- Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection
- Allergic to any component of the therapy.
Key Trial Info
Start Date :
August 28 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2028
Estimated Enrollment :
138 Patients enrolled
Trial Details
Trial ID
NCT07150949
Start Date
August 28 2025
End Date
August 31 2028
Last Update
September 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200030